ASH 2022 | Hot updates in R/R MCL at ASH 2022: data on pirtobrutinib, glofitamab & zilovertamab

Toby Eyre, MBChB (Hons), DipMedEd, MRCP (UK), FRCPath (UK), MD, Oxford University Hospitals NHS Foundation Trust, Oxford, UK, discusses some of the abstracts presented at this year’s ASH meeting which focused on novel agents for mantle cell lymphoma (MCL). Dr Eyre first comments on updated data on pirtobrutinib monotherapy which demonstrated an increase in overall response rate (ORR) and an encouraging safety profile. Dr Eyre then outlines promising results from a follow-up study of glofitamab, suggesting that bispecific antibodies will play a key role in the management of MCL in the future. Lastly, Dr Eyre comments on a trial investigating zilovertamab in combination with ibrutinib, and anticipates that this study will also produce encouraging results. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.